The anti-infective medicine sales in Italy are projected to experience a slight decline from 2024 to 2028, with values moving from 2.73 billion USD in 2024 to 2.71 billion USD in 2028. This reflects a stagnant market with a negligible annual drop. As of 2023, actual sales stood at a baseline, moving into the forecast period.

The year-on-year percentage variation indicates stability in sales with minimal declines. The compound annual growth rate (CAGR) for the five-year forecast hovers close to zero, portraying a consistent yet slightly downward trend in sales.

Future trends to watch for:

Emerging infectious diseases and their impact on sales.
Innovations in pharmaceutical therapies altering market dynamics.
Regulatory changes within the European Union potentially affecting market access.
Economic factors influencing healthcare expenditure in Italy.